Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L V Bauer

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Vaccine|March 8, 2025
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeuticsGiulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Lancet (London, England)|March 14, 2024
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaignMarianne Shawe-Taylor, David Greenwood, Agnieszka Hobbs, et al.
Nature Microbiology|September 19, 2018
Mini viral RNAs act as innate immune agonists during influenza virus infectionAartjan J W Te Velthuis, Joshua C Long, David L V Bauer, et al.
Plos Biology|January 21, 2025
Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasionHarriet V Mears, George R Young, Theo Sanderson, et al.
The Lancet. Infectious Diseases|December 9, 2023
SARS-CoV-2 mucosal neutralising immunity after vaccinationEdward J Carr, Guilia Dowgier, David Greenwood, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|April 28, 2023
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerMary Y Wu, Scott T C Shepherd, Annika Fendler, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Vaccine|March 8, 2025
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeuticsGiulia Dowgier, Agnieszka Hobbs, David Greenwood, et al.
Lancet (London, England)|March 14, 2024
Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaignMarianne Shawe-Taylor, David Greenwood, Agnieszka Hobbs, et al.
Nature Microbiology|September 19, 2018
Mini viral RNAs act as innate immune agonists during influenza virus infectionAartjan J W Te Velthuis, Joshua C Long, David L V Bauer, et al.
Plos Biology|January 21, 2025
Emergence of SARS-CoV-2 subgenomic RNAs that enhance viral fitness and immune evasionHarriet V Mears, George R Young, Theo Sanderson, et al.
The Lancet. Infectious Diseases|December 9, 2023
SARS-CoV-2 mucosal neutralising immunity after vaccinationEdward J Carr, Guilia Dowgier, David Greenwood, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
The Lancet. Infectious Diseases|September 14, 2024
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling studyTimothy W Russell, Hermaleigh Townsley, Joel Hellewell, et al.
Lancet (London, England)|June 22, 2023
Independent SARS-CoV-2 staff testing protected academic and health-care institutions in northwest LondonChris Bailey, Theo Sanderson, Hermaleigh Townsley, et al.
Lancet (London, England)|January 29, 2022
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.
Cancer Cell|April 28, 2023
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerMary Y Wu, Scott T C Shepherd, Annika Fendler, et al.
Pageof 4